Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Germira Di Gioia
Observed names:
G. Di Gioia,
Germira di Gioia
Institution:
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Observed institution:
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
OpenAlex ID:
A5043591815
Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors
2020
·
Michela Piezzo
, Stefania Cocco
, et al.
·
International Journal of Molecular Sciences
·
232
PDF
Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives
2020
·
Stefania Cocco
, Michela Piezzo
, et al.
·
International Journal of Molecular Sciences
·
137
PDF
Targeting Autophagy in Breast Cancer
2020
·
Stefania Cocco
, Alessandra Leone
, et al.
·
International Journal of Molecular Sciences
·
121
PDF
Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
2020
·
Michela Piezzo
, Paolo Chiodini
, et al.
·
International Journal of Molecular Sciences
·
119
PDF
Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center
2021
·
Michela Piezzo
, Roberta D’Aniello
, et al.
·
Pharmaceutics
·
11
PDF
CDK 4/6 inhibitors (CDKi) + endocrine therapy (ET) in ER-positive metastatic breast cancer (mBC) patients according ET sensitivity: A systematic review and meta-analysis.
2019
·
Michela Piezzo
, Maria Riemma
, et al.
·
Journal of Clinical Oncology
PerTe: efficacy and safety of pertuzumab in “real life setting” for the neoadjuvant treatment of HER2-positive breast cancer patients
2017
·
D. Cianniello
, A. Prudente
, et al.
·
Annals of Oncology
PDF
Show more works
View as search
Works count:
7
Citation count:
620
H-index:
5
I10-index:
5
Year
Topic
Type